In CAR T cell-treated lymphomas, the T cell rich get richer

In patients with large B cell lymphomas, immune features of the tumor microenviroment predict clinical outcomes after CAR T cell therapy; as the number of patients treated with CAR T cells is set to increase, refinement of these and other biomarkers will be crucial.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2022-09, Vol.28 (9), p.1757-1758
Hauptverfasser:	Anagnostou, Theodora, Brody, Joshua D.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/53 692/308/575 Antigens B-cell lymphoma Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell therapy Chemokines Clinical outcomes Clinical trials Cytokines Cytotoxicity Infectious Diseases Lymphocytes Lymphocytes T Lymphoma Medicine Metabolic Diseases Molecular Medicine Multiple myeloma Neurosciences Neurotoxicity News & Views news-and-views Patients Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with large B cell lymphomas, immune features of the tumor microenviroment predict clinical outcomes after CAR T cell therapy; as the number of patients treated with CAR T cells is set to increase, refinement of these and other biomarkers will be crucial.
ISSN:	1078-8956 1546-170X
DOI:	10.1038/s41591-022-01922-z